Trial Profile
A randomized controlled trial comparing safety and efficacy of carboplatin and paclitaxel plus or minus sorafenib (BAY 43-9006) in chemonaive patients with stage IIIB-IV non-small cell lung cancer (NSCLC)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 10 Feb 2021
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Acronyms ESCAPE
- Sponsors Bayer
- 29 Jul 2019 Status changed to discontinued.
- 22 Mar 2011 New source identified and integrated (Australian New Zealand Clinical Trials Registry).
- 08 Mar 2010 Results published in the Journal of Clinical Oncology.